Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment
- 2 October 2016
- book chapter
- review article
- Published by Springer Science and Business Media LLC in Cancer treatment and research
- Vol. 169, 321-361
- https://doi.org/10.1007/978-3-319-40320-5_16
Abstract
Waldenström macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder with unique clinicopathologic characteristics. Over the past decade, remarkable progress has occurred on both the diagnostic and therapeutic fronts in WM. A deeper understanding of the disease biology emanates from the seminal discoveries of myeloid differentiation primary response 88 (MYD88) L265P somatic mutation in the vast majority of cases and C-X-C chemokine receptor, type 4, mutations in about a third of patients. Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamentarium continues to expand. Acknowledging the paucity of high-level evidence from large randomized controlled trials, herein, we evaluate the genomic aberrations and provide a strategic framework for the management in the frontline as well as the relapsed/refractory settings of symptomatic WM.This publication has 100 references indexed in Scilit:
- Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalitiesLaboratory Investigation, 2012
- Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemiaLeukemia, 2012
- Temporal and geographic variations of Waldenstrom macroglobulinemia incidenceCancer, 2011
- Analysis of the coding genome of diffuse large B-cell lymphomaNature Genetics, 2011
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphomaNature, 2011
- Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapyCancer Genetics and Cytogenetics, 2010
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphomaNature, 2009
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003